Targeted Oncology

Durable 3-Year Superiority of N-AVD in Advanced Hodgkin Lymphoma

In December 2025, the FDA accepted for priority review the supplemental biologics license application for nivolumab-AVD for the treatment of adult and pediatric patients 12 years and older with ...
Business Wire

Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to ...
Business Wire

Aviceda Announces Successful Submission of an Investigational New Drug (IND) and Fast Track Designation (FTD) Application for AVD-104 for the Treatment of Geographic Atrophy ...

Aviceda Therapeutics has completed a key regulatory milestone for its HALOS™ (High-Affinity Ligands of Sigelcs) technology platform and its lead ophthalmic drug candidate, AVD-104, a novel ...